RIVFLOZA's Patent Review Period Locked In by FDA
Published Date: 6/16/2025
Notice
Summary
The FDA has set the official review period for RIVFLOZA, a new drug, so its patent can be extended. This helps the drug maker get extra time to protect their invention before generic versions can appear. If you’re involved in drug patents or healthcare, this timing update matters for when RIVFLOZA stays exclusive and when competition can start.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
Patent extension gives maker extra exclusivity
The FDA has set the regulatory review period for RIVFLOZA so the drug’s patent can be extended. If you own or manage the patent for RIVFLOZA, this lets you get extra time to protect the invention before competitors can enter the market.
Generic competition may be delayed
The FDA’s determination supports a patent extension for RIVFLOZA, which means generic versions may not be able to appear as soon. If you are a patient, health care provider, or payer, the timing for when competition starts for RIVFLOZA could be later because of this extension.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-19350, Nonclinical Testing Terminology
The FDA is updating its rules to replace the words “animal” tests with “nonclinical” tests, making room for new, smarter ways to check drug safety without relying only on animal testing. This change affects drug makers and researchers but won’t add new costs or requirements. The rule kicks in on February 4, 2027, and comments are open until December 7, 2026.
2026-19349, Nonclinical Testing Terminology
The FDA wants to update its rules by swapping out the word “animal” tests for “nonclinical” tests to better reflect modern science. This change affects drug safety testing rules, encourages new testing methods that might use fewer animals, and doesn’t add any new costs or requirements. Anyone interested can comment on these changes until December 7, 2026.
Previous / Next Documents
Previous: 2025-11039, Determination of Regulatory Review Period for Purposes of Patent Extension; VOWST
The FDA has officially set the review period for VOWST, a special medicine made from human biological material. This means the company behind VOWST can ask for extra patent time to protect their invention. If approved, this could give them more time to make money before others can copy it.
Next: 2025-11041, Determination of Regulatory Review Period for Purposes of Patent Extension; ROLVEDON
The FDA has officially set the review period for ROLVEDON, a medicine that helps people, so its patent can be extended. This means the company behind ROLVEDON gets more time to protect their invention and keep making money before others can copy it. If you’re in the business of making or selling medicines, this update affects when new versions can enter the market.